Literature DB >> 103491

Susceptibility of the anaerobic bacteria, group D streptococci, Enterobacteriaceae, and Pseudomonas to semisynthetic penicillins: carbenicillin, piperacillin, and ticarcillin.

G R Monif, P R Clark, J J Shuster, H Baer.   

Abstract

Sodium piperacillin T-1220, a new semisynthetic penicillin, was tested in vitro against 297 clinical isolates of anaerobic bacteria and 669 aerobic bacteria by the conventional agar dilution method and compared with carbenicillin and ticarcillin. At a 100-mug/ml concentration the three drugs showed comparable effectiveness against the anaerobes tested. However, at 20 mug/ml, piperacillin was the most effective drug against Bacteroides fragilis, peptostreptococci, and group D streptococci. At this drug concentration only 48% of the B. fragilis strains exhibited susceptibility to carbenicillin only, 64% exhibited susceptibility to ticarcillin but 90% exhibited susceptibility to piperacillin. Similar findings were observed with peptostreptococci and group D streptococci. On a weight basis piperacillin was statistically shown to be the most effective antibiotic of the three tested against these anaerobes. At 20 mug/ml, piperacillin exhibited a statistically significant difference (P < 0.01) over carbenicillin and ticarcillin for Serratia marcescens, Escherichia coli, Klebsiella species, Klebsiella pneumoniae, Pseudomonas isolates, and Citrobacter diversus. At both 20- and 100-mug/ml concentrations, piperacillin appeared to be the most effective (calculated P < 0.01) upon Klebsiella species, K. pneumoniae, S. marcescens, and C. freundii in activity over ticarcillin and carbenicillin.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 103491      PMCID: PMC352528          DOI: 10.1128/AAC.14.5.643

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  5 in total

1.  Carbenicillin therapy of gram-negative bacilli infections.

Authors:  G P Bodey; V Rodriguez; J K Luce
Journal:  Am J Med Sci       Date:  1969-06       Impact factor: 2.378

2.  Carbenicillin therapy of severe Pseudomonas aeruginosa infections.

Authors:  C O Solberg; K M Kjellstrand; J M Matsen
Journal:  J Chronic Dis       Date:  1971-06

3.  Piperacillin, a new penicillin active against many bacteria resistant to other penicillins.

Authors:  K P Fu; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1978-03       Impact factor: 5.191

4.  In vitro activity of piperacillin, a new semisynthetic penicillin with an unusually broad spectrum of activity.

Authors:  L Verbist
Journal:  Antimicrob Agents Chemother       Date:  1978-03       Impact factor: 5.191

5.  Clindamycin and Carbenicillin in treatment of patients with intraabdominal and female genital tract infections.

Authors:  R M Swenson; B Lorber
Journal:  J Infect Dis       Date:  1977-03       Impact factor: 5.226

  5 in total
  8 in total

1.  Evaluation of piperacillin sodium in the treatment of infections in immune compromised patients.

Authors:  D A Kelly; J J Fennelly
Journal:  Ir J Med Sci       Date:  1982-08       Impact factor: 1.568

2.  Penetration of piperacillin into bronchial mucosa and sputum.

Authors:  G E Marlin; K R Burgess; J Burgoyne; G R Funnell; M D Guinness
Journal:  Thorax       Date:  1981-10       Impact factor: 9.139

3.  Statistical comparison of the antibacterial activities of broad-spectrum penicillins against gram-negative bacilli.

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1983-08       Impact factor: 5.191

4.  Comparative in vitro appraisal of piperacillin, including its activity against Salmonella typhi.

Authors:  R G Robinson; J Saunders; R Cassel; C S Block; H J Koornhof
Journal:  Antimicrob Agents Chemother       Date:  1980-10       Impact factor: 5.191

Review 5.  Ticarcillin: a review of its pharmacological properties and therapeutic efficacy.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1980-11       Impact factor: 9.546

6.  Prospective randomized trial of piperacillin monotherapy versus carboxypenicillin-aminoglycoside combination regimens in the empirical treatment of serious bacterial infections.

Authors:  M J Gribble; A W Chow; S C Naiman; J A Smith; W R Bowie; S L Sacks; L Grossman; N Buskard; G H Growe; L H Plenderleith
Journal:  Antimicrob Agents Chemother       Date:  1983-09       Impact factor: 5.191

7.  Clinical evaluation of the therapeutic efficacy and tolerability of piperacillin.

Authors:  B Lutz; W Mogabgab; B Holmes; B Pollock; R Beville
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

8.  Susceptibility of anaerobic bacteria to nine antimicrobial agents and demonstration of decreased susceptibility of Clostridium perfringens to penicillin.

Authors:  T J Marrie; E V Haldane; C A Swantee; E A Kerr
Journal:  Antimicrob Agents Chemother       Date:  1981-01       Impact factor: 5.191

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.